Physician profile
Anil Verma
NPI 1174628366
$978.00
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $172 · 2021: $169 · 2022: $220 · 2023: $125 · 2024: $49.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $344.53 | 2019-2020 | |
| Abbvie INC. | $247.27 | 2021-2023 | Qulipta |
| Janssen Pharmaceuticals, INC | $110.80 | 2023 | Xarelto |
| Novo Nordisk INC | $71.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $70.99 | 2021-2022 | |
| Medtronic, INC. | $27.48 | 2024 | Micra |
| Takeda Pharmaceuticals U.S.A., INC. | $24.87 | 2019 | |
| Abiomed | $21.62 | 2024 | Impella |
| Glaxosmithkline, LLC. | $19.18 | 2019 | |
| Cook Medical LLC | $13.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.86 | 2021 | |
| Abbott Laboratories | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.